Biohaven's Obesity Program Gains Analyst Confidence Despite SMA Trial Setback
Baird maintains an Outperform rating for Biohaven, encouraged by positive body composition changes observed in a Phase 3 SMA trial, signaling potential in the upcoming Phase 2 obesity trial.
© Copyright 2025. All Rights Reserved by MedPath